Medical complications after spinal cord injury: Spasticity, pain, and endrocrine/metabolic changes

Topics in Spinal Cord Injury Rehabilitation

Volumn 10, Issue 2, 2004, Pages 86-106

  Ragnarsson, Kristjan T ^a   Stein, Adam B ^a   Spungen, Ann M ^a   Bauman, William A ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Classification systems; Coronary heart disease; Diabetes mellitus; HDL cholesterol; Impaired glucose tolerance; Pain; Spasticity; Spinal cord injury

Indexed keywords

4 AMINOPYRIDINE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BACLOFEN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CARBAMAZEPINE; CLONIDINE; DANTROLENE; DESIPRAMINE; DIAZEPAM; DOXEPIN; FLUOXETINE; GABAPENTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMIPRAMINE; INSULIN; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; POTASSIUM CHANNEL BLOCKING AGENT; SERTRALINE; STEROID; TIZANIDINE; TRIACYLGLYCEROL; UNINDEXED DRUG;

ASTHENIA; ATHEROGENESIS; BODY COMPOSITION; BODY MASS; CARBOHYDRATE METABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE CLASSIFICATION; DIZZINESS; ENDOCRINE DISEASE; FATIGUE; HUMAN; HYPERINSULINEMIA; HYPOTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID METABOLISM; LIVER TOXICITY; METABOLIC DISORDER; NERVE BLOCK; NEUROPATHIC PAIN; NOCICEPTION; OBESITY; PAIN; QUADRIPLEGIA; QUALITY OF LIFE; REVIEW; RISK FACTOR; SEDATION; SIDE EFFECT; SPASTICITY; SPINAL CORD INJURY; TRIACYLGLYCEROL BLOOD LEVEL; XEROSTOMIA;

EID: 11144220034     PISSN: 10820744     EISSN: None     Source Type: Journal    
DOI: 10.1310/0UP0-AVGJ-DUHN-R52A     Document Type: Review

References (111)

1. Dalyan M, Sherman A, Cardenas DD. Factors associated with contractures in acute spinal cord injury. Spinal Cord. 1998;36:405-408.
2. Priebe MM, Goetz, LL, Wuermser L. Spasticity following spinal cord injury. In: Kirshblum S, Campagnolo DI, DeLisa JA, eds. Spinal Cord Medicine. Philadelphia, PA: Lippincott, Williams and Wilkins; 2002:221-233.
3. Carlson SJ. A Neurophysiologic Analysis of Inhibitive Casting. Physical and Occupational Therapy in Pediatrics, vol 1. The Hayworth Press, Inc; 1985:31-42.
4. Price R, Lehmann JF, Boswell-Bessette S, et al. Influence of cryotherapy on spasticity at the human ankle. Arch Phys Med Rehabil. 1993;73:300-304.
5. Stein AB, Pomerantz F, Schechtman J. Evaluation and management of spasticity in spinal cord injury. Top Spinal Cord Inj Rehabil. 1997;2(4):70-83.
6. Weingarden SI, Belen JG. Clonidine transdermal system for treatment of spasticity in spinal cord injury. Arch Phys Med Rehabil. 1992;73:876-877.
7. Yablon SA, Sipski ML. Effect of transdermal clonidineon spinal spasticity. Am J Phys Med Rehabil. 1993;72:154-157.
8. Nance P, Bugaresti J, Shellenberger K, et al. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. Neurology. 1994;44(suppl):S44-52.
9. Nance PW, Sheremata WA, Lynch SG, et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol. 1997;54(6):731-736.
10. Grunthal M, Mueller M, Olsen WL, et al. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord. 1997;35:686-689.
11. Cutter N, Scott D, Johnson J, et al. Gabapentin effect in spasticity in multiple sclerosis: a placebo controlled, randomized trial. Arch Phys Med Rehabil. 2000;81:164-169.
12. Potter PJ, Hayes KC, Segal JL, et al. Randomized double blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury. J Neurotrauma. 1998;15(10):837-849.
13. Hansebout RR, Blight AR, Fawcett S, et al. 4-aminopyridine in chronic spinal cord injury: a controlled double-blind crossover study in eight patients. J Neurotrauma. 1993;10:1-18.
14. Kroin JS, Ali A, York M, et al. The distribution of medication along the spinal canal after chronic intrathecal administration. Neurosurgery. 1993;78:226-252.
15. Remy-Nevis O, Barbeau H, Daniel O, et al. Effects of intrathecal clonidine injection on spinal reflexes and human locomotion in incomplete paraplegic subjects. Exp Brain Res. 1999;129:433-440.
16. Middleton JW, Siddall PJ, Walker S, et al. Intrathecal clonidine and baclofen in the management of spasticity and neuropathic pain following spinal cord injury: a case study. Arch Phys Med Rehabil. 1996;77:824-826.
17. Penn RD. Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J Neurosurg. 1992;77:236-240.
18. Meythaler JM, Guin-Renfroe S, Brunner RC, Hadley MN. Intrathecal baclofen for spastic hypertonia from stroke. Stroke. 2001;32(9):2099-2107.
19. Meythaler JM, Guin-Renfroe S, Law C, et al. Continuously infused intrathecal baclofen over 12 months for spastic hypertonia in adolescents and adults with cerebral palsy. Arch Phys Med Rehabil. 2001;82:155-161.
20. Shaari CM, Sanders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve. 1993;16:64-69.
21. Simpson DM. Clinical trials of botulinum toxin in the treatment of spasticity. Muscle Nerve. 1997;6(suppl):S169-175.
22. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity and immunology. Muscle Nerve. 1997;6(suppl):S146-168.
23. Bryce TN, Ragnarsson KT. Epidemiology and classification of pain after spinal cord injury. Top Spinal Cord Inj Rehabil. 2001;7(2):1-17.
24. Bryce TN, Ragnarsson KT. Pain after spinal cord injury. Phys Med Rehabil Clin N Am. 2002;11:157-168.
25. Siddall PJ, Yezierski RP, Loesser JD. Pain following spinal cord injury: clinical features, prevalence and taxonomy. MSP Newsletter. 2000;3:3-7.
26. Siddall PJ, Taylor D, Cousins M. Classification of pain following spinal cord injury. Spinal Cord. 1997;35:69-75.
27. Sriwatankul K, Ketvie W, Lasagna L, et al. Studies with different types of visual analog scales for measurement of pain. Clin Pharmacol Ther. 1983;34:234-239.
28. Meldrun ML. A capsule history of pain management. JAMA. 2003;290:2477-2475.
29. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain. 1986;25:171-186.
30. Apple DA. Pain above the injury level. Top Spinal Cord Inj Rehabil. 2001;7:18-29.
31. Cardenas DD, Rosenbluth J. At and below level pain in spinal cord injury: mechanisms and diagnosis. Top Spinal Cord Inj Rehabil. 2001;7:30-40.
32. Donovan WH, Dimitrijevic MR, Dham L, Dimitrijevic M. Neurophysiological approached to chronic pain following spinal cord injury. Paraplegia. 1982;20:135-146.
33. Merskey H, Bogduk N. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms, 2nd ed. Seattle: IASP Press; 1994:40-42.
34. Schwartzman RJ. New treatments for reflex sympathetic dystrophy. N Engl J Med. 2000;243:654-656.
35. Kenler MA, Barendse CAN, VanKleef N, et al. Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy. N Engl J Med. 2000;343:618-684.
36. VanHilten BJ, Vande Bek W-JT, Hoff JI, et al. Intrathecal Baclofen for treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med. 2000;243:625-630.
37. Bryce TN, Ragnarsson KT. Pain management in persons with spinal cord disorders. In: Lin VW, ed. Spinal Cord Medicine, Principles and Practice, chapter 33. New York: Demos; 2003:441-460.
38. Bockenek WL, Stewart PJB. Pain in patients with spinal cord injury. In: Kirshblum S, Campagnolo DI, DeLisa JA, eds. Spinal Cord Medicine. Philadelphia, PA: Lippincott, Williams and Wilkins, 2002:389-408.
39. Ragnarsson KT. Management of pain in persons with spinal cord injury. J Spinal Cord Med. 1997;20:186-199.
40. Kezar LB, Ness TJ. Systemic medications. Top Spinal Cord Inj Rehabil. 2001;7(2):57-72.
41. Carrazana E, Mikoshiba I. Rationale and evidence for the use of oxcarbazepine in neuropathic pain. J Pain Symptom Manage. 2003;25(5 suppl):S31-35.
42. Fox A, Gentry C, Patel S, Kesingland A, Bevan S. Comparative activity of the anti-convulsants oxcarbazepine, carbamazepine, lamotrigine and gabapentin in a model of neuropathic pain in the rat and guinea-pig. Pain. 2003;105(1-2):355-362.
43. Drewes AM, Andreasen A, Poulsen LH. Valproate for treatment of chronic central pain after spinal cord injury. A double-blind cross-over study. Paraplegia. 1994;32(8): 565-569.
44. Finnerup NB, Sindrup SH, Bach FW, Johannesen IL, Jensen TS. Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain. 2002;96(3):375-383.
45. Cardenas DD, Warms CA, Turner JA, Marshall H, Brooke MM, Loeser JD. Efficacy of amitriptylini; for relief of pain in spinal cord injury: results of a randomized controlled trial. Pain. 2002;96(3):365-373.
46. Tai Q, Kirshblum S, Chen B, Millis S, Johnston M, DeLisa JA. Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. J Spinal Cord Med. 2002;25(2):100-105.
47. Harden RN, Brenman E, Saltz S, Houle TT. Topiramate in the management of spinal cord injury pain: a double-blind, randomized, placebo-controlled pilot study. In: Yezierski RP, Burchiel KJ, eds. Spinal Cord Injury Pain: Assessment, Mechanisms, Management. Progress in Pain Research and Management, vol. 23. Seattle: IASP Press; 2002:393-407.
48. Chiou-Tan FY, Tuel SM, Johnson JC, Priebe MM, Hirsh DD, Strayer JR. Effect of mexiletine on spinal cord injury dysesthetic pain. Am J Phys Med Rehabil. 1996;75(2):84-87.
49. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med. 2003;349:1943-1953.
50. Hegarty A, Portenoy R. Pharmacotherapy of neuropathic: pain. Semin Neurol. 1994;14:213-224.
51. Eide P, Stubhaug A, et al. Central dysesthesia pain after traumatic spinal cord injury is dependent on N-methyl-D-aspartate receptor activation. Neurosurgery. 1995;37:1080-1087.
52. Karst N, Salin K, Burstein S, et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA. 2003;290:1757-1762.
53. Potter PJ, Hayes KC, et al. Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine; 3 cases. Spinal Cord. 1998;36:147-155.
54. Penn RD. Treatment of pain in persons with spinal cord injury: spinal cord stimulation and intrathecal drugs. Top Spinal Cord Inj Rehabil. 2001;7(2):51-56.
55. Sandford PR, Benes PS. Use of capsaisin in the treatment of radicular pain in spinal cord injury. J Spinal Cord Med. 2000;23:238-243.
56. Turner JA, Cardenas DD, Warms CA, McClellan CB. Chronic pain associated with spinal cord injuries: a community survey. Arch Phys Med Rehabil. 2001;82(4):501-509.
57. Lammertse DP, Falci SP. Surgical management of central pain in persons with spinal cord injury: the dorsal root entry zone (DREZ) procedure. Top Spinal Cord Inj Rehabil. 2001;7(2):41-50.
58. Edgar R, Best L, et al. Computer assisted DREZ microcoagulation: post traumatic spinal deafferentation pain. J Spinal Disord. 1993;6:48-56.
59. Friedman AH, Nashold BS Jr. DREZ lesions for relief of pain related to spinal cord injury. J Neurosurg. 1986;65:465-469.
60. Falci S, Best L, Lammertse D, Starnes C. Surgical treatment of spinal cord injury (SCI) pain using a new technique of intramedullary electrical analysis [abstract 34]. J Spinal Cord Med. 1999;22:39.
61. Wegener ST, Haythornthwaite JA. Psychological and behavioral issues in the treatment of pain after spinal cord injury. Top Spinal Cord Inj Rehabil. 2001;7(2):73-83.
62. Craig AR, Hancock K, et al. Long term psychological outcomes in spinal cord injured persons: results of controlled trial using cognitive behavioral therapy. Arch Phys Med Rehabil. 1997;78:33-38.
63. Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990;263:2893-2898.
64. Bauman WA. Carbohydrate and lipid metabolism after spinal cord injury. Top Spinal Cord Inj Rehabil. 1997;2:1-22.
65. Bauman WA, Adkins RH, Spungen AM, et al. The effect of residual neurological deficit on oral glucose tolerance in persons with chronic spinal cord injury. Spinal Cord. 1999;37:765-771.
66. Bauman WA, Spungen AM. Disorders of carbohydrate and lipid metabolism in veterans with paraplegia or quadriplegia: a model of premature aging. Metabolism. 1994;43:749-756.
67. Duckworth WC, Solomon SS, Jallepalli P, et al. Glucose intolerance due to insulin resistance in patients with spinal cord injuries. Diabetes. 1980;29:906-910.
68. Duckworth WC, Jallepalli P, Solomon SS. Glucose tolerance in spinal cord injury. Arch Phys Med Rehabil. 1983;64:107-110.
69. Tharion G, Prasad KR, Gopalan L, Bhattacharji S. Glucose intolerance and dyslipidaemias in persons with paraplegia and tetraplegia in South India. Spinal Cord. 1998;36:228-230.
70. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28:1039-1057.
71. WHO Expert Committee on Diabetes Mellitus. Second Report. WHO Tech Rep Ser No 646;1980.
72. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-1197.
73. Lipman RL, Raskin P, Love T, et al. Glucose intolerance during decreased physical activity in man. Diabetes. 1972;21:101-107.
74. Lipman RL, Schnure JJ, Bradley EM, et al. Impairment of peripheral glucose utilization in normal subjects by prolonged bed rest. J Lab Clin Med. 1970;76:221-230.
75. Helmrich SP, Ragland DR, Leung RW, et al. Physical activity and reduced occurrence of NIDDM. N Engl J Med. 1991;325:147-152.
76. Manson JE, Nathan DM, Krolewski AS, et al. A prospective study of exercise and incidence of diabetes among US male physicians. JAMA. 1992;268:63-67.
77. Stuart CA, Shangraw RE, Prince MJ, et al. Bedrest-induced insulin resistance occurs primarily in muscle. Metabolism. 1988;37:802-806.
78. Misbin RI, Moffa AM, Kappy MS. Insulin binding to monocytes in obese patients treated with carbohydrate restriction and changes in physical activity. J Clin Endocrinol Metab. 1983;56:273-278.
79. Norton ES, Runge CF, Sims EA. Endocrine and metabolic effects of experimental obesity in man. Recent Prog Horm Res. 1970;29:457-496.
80. Nagulesparan MPJ, Savage R, Unger R, et al. A simplified method using somatostatin to assess in vivo insulin resistance over a range of obesity. Diabetes. 1980;28:1272-1284.
81. Rabinowitz D, Zierler KL. Forearm metabolism in obesity and its response to intra-arterial insulin. Characterization of insulin resistance and evidence for adaptive hyper-insulinism. J Clin Invest. 1962;41:2173-2181.
82. Hotamisligil GS, Murray DL, Choy LN, et al. TNF-a inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA. 1994;91:4852-4858.
83. Aksnes AK, Hjeltnes N, Wahlstrom EO, et al. Intact glucose transport in morphologically altered denervated skeletal muscle from quadriplegic patients. Am J Physiol. 1996;271:E593-E600.
84. Lillioja S, Young AA, Cutler CL, et al. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest. 1987;80:415-424.
85. Bourn DM, Mann JI, McSkimming BJ, et al. Impaired glucose tolerance and NIDDM: Does a lifestyle intervention program have an effect? Diabetes Care. 1994;17:1311-1319.
86. Pan X, Li G, Hu Y, et al. Effect of Dietary and/or Exercise Interventions on Incidence of Diabetes in Subjects with ICT: the Da-Qing IGT and Diabetes Study [abstract]. Kobe, Japan: International Diabetes Federation Congress; November 1994.
87. LaPorte RE, Brenes G, Dearwater S, et al. HDL cholesterol across a spectrum of physical activity from quadriplegia to marathon running [letter]. Lancet. 1983;1212-1213.
88. Dallmeijer AJ, van der Woude LH, van Kamp GJ, et al. Changes in lipid, lipoprotein and apolipoprotein profiles in persons with spinal cord injuries during the first 2 years post-injury. Spinal Cord 1999;37:96-102.
89. Apstein MD, George BC. Serum lipids during the first year following acute spinal cord injury. Metabolism. 1998;47:367-370.
90. Grundy SM, DeWitt S, Goodman MD, et al. The place of HDL cholesterol management. A perspective from the National Cholesterol Education Program. Arch Intern Med. 1989;149:505-510.
91. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
92. Bauman WA, Spungen AM, Zhong YG, et al. Depressed serum high density lipoprotein cholesterol levels in veterans with spinal cord injury. Paraplegia. 1992;30:697-703.
93. Brenes G, Dearwater S, Shapera R, et al. High density lipoprotein cholesterol concentrations in physically active and sedentary spinal cord injured patients. Arch Phys Med Rehabil. 1986;67:445-450.
94. Hooker SP, Wells CL. Effects of low- and moderate-intensity training in spinal cord-injured persons. Med Sci Sports Exerc. 1989;21:18-22.
95. Bauman WA, Adkins RH, Spungen AM, et al. Is immobilization associated with an abnormal lipoprotein profile? Observations from a diverse cohort. Spinal Cord. 1999;37:485-493.
96. Johansson J, Walldius G, Carlson LA. Close correlation between high-density lipoprotein and triglycerides in normotriglyceridemia. J Int Med. 1992;232:43-51.
97. Golay A, Zech L, Shi MZ, et al. High density lipoprotein (HDL) metabolism in noninsulin-dependent diabetes mellitus: measurement of fHDL turnover using tritiated HDL. J Clin Endocrinol Metab. 1987;65:512-518.
98. Reaven GM. NIDDM, abnormal lipoprotein metabolism, and atherosclerosis. Metabolism. 1987;36(suppl 1):1-8.
99. Maki KC, Briones ER, Lanbein WE, et al. Associations between serum lipids and indicators of adiposity in men with spinal cord injury. Paraplegia. 1995;33:102-109.
100. Bauman WA, Adkins RH, Spungen AM, et al. The effect of residual neurological deficit on serum lipoproteins in individuals with chronic spinal cord injury. Spinal Cord. 1998;36:13-17.
101. Schmid A, Halle M, Stutzle C, et al. Lipoproteins and free plasma catecholamines in spinal cord injured men with different injury levels. Clin Physiol. 2000;20:304-310.
102. Bauman WA, Adkins RH, Spungen AM, et al. Ethnicity effect on the serum lipid profile in persons with spinal cord injury. Arch Phys Med. 1998;79:176-180.
103. Bauman WA, Adkins RH, Spungen AM, et al. Individuals with extreme inactivity do not have abnormal serum Lp(a) levels. Harm Metab Res. 1998;30:601-603.
104. Hartung GH. Physical activity and high density lipoprotein cholesterol. J Sports Med Phys Fitness. 1995;35:1-5.
105. Bauman A, Owen N. Habitual physical activity and cardiovascular risk factors. Med J Aust. 1991;154:22-28.
106. Steinberg D, Pearson TA, Kuller LH. Alcohol and atherosclerosis. Ann Intern Med. 1991;114:967-976.
107. Frisk MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
108. Randomized trial of cholesterol lowering in 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
109. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
110. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
111. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 984;251:365-374.